190 results on '"Colomba E"'
Search Results
2. Effects of leaf and stem maturation on nutritional value in Megathyrsus maximus
3. IO-Synthesise RCC: relationship between baseline health-related quality of life and clinical outcomes of nivolumab in patients with previously treated metastatic renal cell carcinoma using pooled real-world data from France and Germany
4. Urachal carcinoma: a large retrospective multicentric study from the French Genito-Urinary Tumor Group
5. Spécificités cliniques des tumeurs de vessie n’infiltrant pas le muscle métastatique d’emblée : étude observationnelle multicentrique merinos
6. 550P Immunoprofiling of mismatch repair-deficient (MMRd) endometrial cancer (EC) patients (pts): Immune checkpoint inhibitor (ICI)-responders (R) versus non-responders (NR)
7. 1405P Circulating tumor DNA in advanced prostate cancer: Focus on high blood tumor mutational burden (h-bTMB)
8. 1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC)
9. 1480P Baseline levels of proinflammatory cytokines according to body mass index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (NIVO) within the NIVOREN trial
10. 1762P MERINOS: Metastatic non muscle invasive urothelial carcinoma - An observational study
11. 1380P High Sonic Hedgehog (HH) signalling activity, low androgen receptor activity and clonal evolution are associated with resistance to androgen-receptor axis inhibitors in patients with metastatic prostate cancer
12. 574P Myriad MyChoice plus intermediate performance to discriminate platinum-resistant high-grade ovarian cancer patients
13. 20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC)
14. Relationship between seed yield and its component characters in Cenchrus spp.
15. Relationship between seed yield and its component characters in Cenchrus spp.
16. Morphological evaluation of buffelgrass cultivar 'Lucero INTA-PEMAN' in drought conditions
17. Evaluación morfológica del cultivar de buffelgrass 'Lucero INTA-PEMAN' en condiciones de sequía
18. Severe COVID-19 in patients with hematological cancers presenting with viremia
19. O008/#785 A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775
20. O002/#43 Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (aec): subgroup analysis of patients with DNA mismatch repair deficient (DMMR) tumors
21. Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies
22. 145 Characterization of adverse reactions in patients with advanced endometrial cancer (aec) receiving lenvatinib + pembrolizumab (Study 309/KEYNOTE-775)
23. 697P Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N)
24. 657MO Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study
25. 726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)
26. 1565MO Time-dependent improvement in the clinical outcomes from COVID-19 in cancer patients: An updated analysis of the OnCovid registry
27. 603P Objective computerized cognitive assessment in men with metastatic castrate-resistant prostate cancer (mCRPC) randomly receiving darolutamide or enzalutamide in the ODENZA trial
28. 801P Response to first-line platinum chemotherapy in microsatellite instability high (MSI-H) metastatic endometrial carcinoma
29. 1639P Impact of COVID-19 on ongoing oncological and hematological treatment strategy
30. 655MO A prospective phase II trial of cabazitaxel in male patients with chemotherapy pre-treated metastatic germ-cell tumors: The CABA-GCT study
31. P182 - IO-Synthesise RCC: relationship between baseline health-related quality of life and clinical outcomes of nivolumab in patients with previously treated metastatic renal cell carcinoma using pooled real-world data from France and Germany
32. 748P Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
33. A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB VS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH ADVANCED ENDOMETRIAL CANCER: STUDY 309/KEYNOTE-775
34. First report of Sweet potato leaf curl virus infecting sweet potato in Argentina
35. Determinación del contenido proteÃnico en materiales seleccionados de Cenchrus ciliaris L., Chloris gayana K. y Panicum coloratum L
36. Influencia de un complejo viral en rendimiento y contenido de clorofila de dos variedades de batata.
37. 823P Extended follow-up of a real-world cohort of patients (pts) with BRCA mutation (BRCAm) relapsed epithelial ovarian cancer (EOC) receiving olaparib maintenance therapy: The GINECO RETROLA study
38. Skeletal muscle loss as an adverse event during cabozantinib treatment in patients with metastatic renal cell carcinoma
39. Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC)
40. 1452MO Longitudinal analysis reveals gut microbiota shift during standard therapies in metastatic renal cell carcinoma (mRCC)
41. Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre
42. Individual and combined effects of drought and heat on antioxidant parameters and growth performance in Buffel grass (Cenchrus ciliaris L.) genotypes
43. Identification of IMDC intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma (ccRCC)
44. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study
45. 974P - Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
46. 965P - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC)
47. 967P - Skeletal muscle loss as an adverse event during cabozantinib treatment in patients with metastatic renal cell carcinoma
48. Efficacy of cabozantinib (C) after PD-1/PD-L1 checkpoint inhibitors in metastatic renal cell carcinoma (mRCC): The Gustave Roussy experience
49. 887P - Identification of IMDC intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma (ccRCC)
50. Energy Refurbishment and LCA assessment of a 1970s typical Italian school
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.